Too Many Women Who Need Bone Screening Aren’t Getting It
Too few womens at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.
Boehringer Ingelheim’s combination COPD therapy Stiolto Respimat garners FDA approval
Boehringer Ingelheim announced Tuesday that the FDA approved Stiolto Respimat (tiotropium/olodaterol) as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis or emphysema. The inhalation spray combines the long-acting anticholinergic tiotropium, which is marketed as Spiriva Respimat and Spiriva HandiHaler, with the long-acting beta2-agonist olodaterol, which is sold as Striverdi Respimat.
Insurers Proposing ‘Hefty’ Rate Increases For Some Obamacare Plans
he Wall Street Journal reports that these proposed rate boosts will set the stage for debate regarding the health law’s impact. Wellmark’s South Dakota members are among those likely to see such rate hikes, according to The Associated Press.
Fight over hot new cholesterol drugs may be won in milligrams
Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. But there is at least one significant difference between the two offerings: the dosages in which they will be sold.
Discovery of a treatment to block progression of multiple sclerosis
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. These encouraging results from in vitro tests in humans and in vivo tests in mice were published today in the Annals of Neurology. “We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease’s progression,” said Dr. Alexandre Prat, lead author of the study, researcher at the CRCHUM, and professor in the Department of Neurosciences at the University of Montreal.
More Evidence That High-Fiber Diet May Curb Type 2 Diabetes Risk
People who get a lot of fiber in their diet may be lowering their odds for type 2 diabetes, new research shows.
Novartis digs into health tech with bet on ‘robotic pill’
Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a “robotic pill” for complex biotech drugs that would normally have to be given by injection.
Researchers oppose unvalidated gene panel tests for cancer links
A group of international researchers is making the case that genetic tests that look for multiple hereditary genes suspected of being linked to breast cancer should not be offered until they are proven to be valid and useful in clinical practice.
New Push Ties Cost of Drugs to How Well They Work
Express Scripts Holding Co., a large manager of prescription-drug benefits for U.S. employers and insurers, is seeking deals with pharmaceutical companies that would set pricing for some cancer drugs based on how well they work.
CMS updates Medicaid managed care organization rules
The Centers for Medicare & Medicaid Services (CMS) has released its long-awaited proposed rule that updates its Medicaid managed care organization (MCO) regulations.
FDA Approves Stiolto Respimat
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD.
First drug approved by FDA to treat radiation sickness
The FDA has approved the first drug to treat radiation exposure in the event of a nuclear disaster. Approval of Neupogen®, is the result of research performed by scientists at the University of Maryland School of Medicine (UM SOM) that showed the drug counteracts the effects of radiation to protect blood cells from destruction brought about by radiation that attacks bone marrow.